Value in health regional issues最新文献

{"title":"Assessment of Extent and Quality of Pharmacoeconomic Studies in India Using Quality of Health Economic Studies Score: A Targeted Literature Review","authors":"Neel Patel PharmD ,&nbsp;Samykya Yanamala MPT ,&nbsp;Mahendra Rai MPharm","doi":"10.1016/j.vhri.2023.11.013","DOIUrl":"https://doi.org/10.1016/j.vhri.2023.11.013","url":null,"abstract":"<div><h3>Objectives</h3><p>We assessed the quality of pharmacoeconomic studies conducted in India to report key areas of focus on the findings from the reviewed studies.</p></div><div><h3>Methods</h3><p>A targeted literature review was conducted using well-defined search strategy in PubMed to identify economic studies<span> conducted in India from May 2017 to April 2022. Only economic evaluation studies were included, whereas trial-based cost analyses were excluded. The quality of included studies was assessed using the Quality of Health Economic Studies tool, which comprised 16 evaluation criteria related to objectives, source, funding, perspective, subgroup analysis, scales, and economic modeling related parameters. Based on scores (100 points), studies were rated as good (≥75), fair (50-74), and poor (≤49) quality.</span></p></div><div><h3>Results</h3><p>Search strategy provided 888 studies; 95 of these were economic studies, and 74 were included in the analysis. These 74 studies included budget impact analysis (n = 4), burden of illness (n = 8), cost-benefit analysis (n = 5), cost-consequences analysis (n = 1), cost-effectiveness analysis (n = 55), and cost-utility analysis (n = 1). The average quality score of studies was 64.08. Of the studies, 15 studies were rated as “good,” 51 “fair,” and 8 “poor.” It was observed that primary outcome measures, stating negative outcomes, reporting bias, and implementing statistical and sensitivity analysis significantly affected the quality score.</p></div><div><h3>Conclusions</h3><p>Most of the health economic studies conducted in India are of fair quality, and there is a need for standardization of guidelines and increase in number of Indian peer-reviewed health economics journals. A collaborative effort from pharma companies, policy makers, education experts, curriculum planners, and medical faculty is needed to promote quality economic studies.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"41 ","pages":"Pages 41-47"},"PeriodicalIF":2.0,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139487164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Health-Related Quality of Life and Incurred Costs Among Human Immunodeficiency Virus, Tuberculosis, and Tuberculosis/HIV Coinfected Outpatients in Indonesia","authors":"Lusiana R. Idrus PhD ,&nbsp;Najmiatul Fitria PhD ,&nbsp;Fredrick D. Purba PhD ,&nbsp;Jan-Willem C. Alffenaar PhD, PharmD ,&nbsp;Maarten J. Postma PhD","doi":"10.1016/j.vhri.2023.10.010","DOIUrl":"https://doi.org/10.1016/j.vhri.2023.10.010","url":null,"abstract":"<div><h3>Objectives</h3><p>A growing interest in healthcare costs and patients’ health-related quality of life (HRQoL) exists in the context of the increasing importance of health technology assessment in countries with high numbers of the HIV and tuberculosis (TB) patient populations, such as Indonesia. This study aimed to analyze the HRQoL and out-of-pocket (OOP) costs of HIV, TB, and TB/HIV coinfected participants in a city in Indonesia with a high prevalence of HIV and TB.</p></div><div><h3>Methods</h3><p>A cross-sectional survey was conducted in the voluntary counseling and testing and lung clinics of Bekasi City Public Hospital (Indonesia) from January to March 2018. Patients’ HRQoL was measured using the EQ-5D-5L questionnaire, whereas OOP costs were extracted from a semistructured questionnaire.</p></div><div><h3>Results</h3><p>Of the 460 eligible participants, 82% resided in the city, 48% of them were married, and their median age was 34 years. Less than half were insured, and more than half had no source of income. The median values of health utilities for participants with HIV, TB, and TB/HIV were perceived as potentially high (1.0, 0.9, and 0.8, respectively). The TB/HIV coinfected outpatients had the highest OOP costs (US$94.5), with the largest contribution coming from direct medical OOP expenditures. Taking loans from family members was adopted as a financial strategy to overcome inadequate household incomes and high treatment costs.</p></div><div><h3>Conclusion</h3><p>This study suggests that TB/HIV coinfection potentially lowers HRQoL and increases healthcare costs and the need for economic analysis to underpin cost-effective treatment in such patients.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"41 ","pages":"Pages 32-40"},"PeriodicalIF":2.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212109923001292/pdfft?md5=432fbea61af0cff0fa19fdbdc0dcbcc8&pid=1-s2.0-S2212109923001292-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139399054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan","authors":"Tomomi Maeda BPharm ,&nbsp;Kensuke Moriwaki PhD ,&nbsp;Kosuke Morimoto MS ,&nbsp;Xiuting Mo PhD ,&nbsp;Takashi Yoshioka MD, PhD ,&nbsp;Rei Goto MD, PhD ,&nbsp;Kojiro Shimozuma MD, PhD","doi":"10.1016/j.vhri.2023.11.003","DOIUrl":"https://doi.org/10.1016/j.vhri.2023.11.003","url":null,"abstract":"<div><h3>Objectives</h3><p>The purpose of this study is to examine the cost-effectiveness of nivolumab (NIVO) plus ipilimumab (IPI) combination therapy (NIVO + IPI) compared with the sunitinib (SUN) therapy for Japanese patients with advanced renal cell carcinoma from the perspective of a Japanese health insurance payer.</p></div><div><h3>Methods</h3><p>A lifetime horizon was applied, and 2% per annum was set as the discount rate. The threshold was set as $ 75 000 per quality-adjusted life-year (QALY) gained. For the analytical method, we used a partitioned survival analysis model to estimate the incremental cost-effectiveness ratio (ICER), which is calculated by dividing incremental costs by incremental QALYs. Progression-free survival, progressive disease, and death were set as health states. Additionally, cost parameters and utility weights were set as key parameters. We set the intermediate/poor-risk population as the base case. Scenario analysis was conducted for the intention-to-treat population and the favorable risk population. Furthermore, one-way sensitivity analysis and probabilistic sensitivity analysis were conducted for each population.</p></div><div><h3>Results</h3><p>In the base-case analysis, the QALYs of NIVO + IPI and SUN were 4.32 and 2.99, respectively. NIVO + IPI conferred 1.34 additional QALYs. Meanwhile, the total costs in the NIVO + IPI and SUN were $692 288 and $475 481, respectively. As a result, the ICER of NIVO + IPI compared with SUN was estimated to be $162 243 per QALY gained. The parameter that greatly affected the ICER was the utility weight of progression-free survival in NIVO + IPI.</p></div><div><h3>Conclusions</h3><p>NIVO + IPI for advanced renal cell carcinoma seems to be not cost-effective compared with the SUN in the Japanese healthcare system.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"40 ","pages":"Pages 118-126"},"PeriodicalIF":2.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212109923001243/pdfft?md5=e553f9409f0e8fd85729dd65b18cba17&pid=1-s2.0-S2212109923001243-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139399141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil","authors":"Brígida Dias Fernandes PhD ,&nbsp;Fernanda D’Athayde Rodrigues PhD ,&nbsp;Hérica Núbia Cardoso Cirilo PhD ,&nbsp;Stéfani Sousa Borges MSc ,&nbsp;Bárbara Corrêa Krug MSc ,&nbsp;Livia Fernandes Probst PhD ,&nbsp;Ivan Zimmermann PhD","doi":"10.1016/j.vhri.2023.11.004","DOIUrl":"10.1016/j.vhri.2023.11.004","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aimed to evaluate the cost-effectiveness of the onasemnogene abeparvovec in relation to nusinersen and risdiplam in the treatment of spinal muscular atrophy type 1 from the perspective of the Brazilian Unified Health System.</p></div><div><h3>Methods</h3><p>A Markov model was built on a lifetime horizon. Short-term data were obtained from clinical trials of the technologies and from published cohort survival curves (long term). Costs were measured in current 2022 local currency (R$) values and benefits in quality-adjusted life-years (QALYs). Utility values were derived from type 1 spinal muscular atrophy literature, whereas costs related to technologies and maintenance care in each health state were obtained from official sources of reimbursement in Brazil. Deterministic and probabilistic, as well as scenario, sensitivity analyses were performed.</p></div><div><h3>Results</h3><p>Compared with the less costly strategy (nusinersen), the use of onasemnogene abeparvovec resulted in an incremental cost of R$2.468.448,06 ($975 671.169 – purchasing power parity [PPP]) and a 3-QALY increment and incremental cost-effectiveness ratio of R$742.890,92 ($293 632.774 – PPP)/QALY. Risdiplam had an extended dominance from other strategies, resulting in an incremental cost-effectiveness ratio of R$926.586,22 ($366 239.612 – PPP)/QALY compared with nusinersen. Sensitivity analysis showed a significant impact of the follow-up time of the cohort and the cost of acquiring onasemnogene abeparvovec.</p></div><div><h3>Conclusions</h3><p>Over a lifetime horizon, onasemnogene abeparvovec seems to be a potentially more effective option than nusinersen and risdiplam, albeit with an incremental cost. Such a trade-off should be weighed in efficiency criteria during decision making and outcome monitoring from the perspective of the Brazilian Unified Health System.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"40 ","pages":"Pages 108-117"},"PeriodicalIF":2.0,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139106746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multivariate Relationships Between Health Outcomes and Health System Performance Indicators: An Integrated Factor Analysis With Canonical Correlations","authors":"Yunus Emre Karatas MS ,&nbsp;Songul Cinaroglu PhD","doi":"10.1016/j.vhri.2023.10.009","DOIUrl":"10.1016/j.vhri.2023.10.009","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aimed to investigate the relationships between sets of variables related to health system performance indicators and health outcomes.</p></div><div><h3>Methods</h3><p>The relationships between a set of health outcomes and a set of health system performance indicators of a developing country were examined using multivariate statistical analysis<span> techniques. A combinative strategy of explanatory factor analysis and the canonical correlation coefficient<span> was used to define linear structural relationships between study variables. Province-based data were gathered from2 official statistical records of the Turkish Statistical Institute for the year 2019. Life expectancy at birth, infant mortality rate, and crude death rate were accepted as health outcome indicators.</span></span></p></div><div><h3>Results</h3><p><span>The explanatory factor analysis indicated 2 independent variable groups, namely (1) health-related human resources and capacity and (2) health service utilization characteristics. The results of the canonical correlation analysis illustrated good performance to define sparse linear combinations of the 2 groups of variables. There existed strong positive correlations between health outcomes and health-related human resources and capacity indicators (r</span>_c = 0.83; <em>P</em> &lt; .001) and health service utilization indicators (r_c = 0.59; <em>P</em> &lt; .001).</p></div><div><h3>Conclusions</h3><p>The results of this study support the view that there is a linear and strong positive relationship between health outcomes and health-related human resources and capacity indicators. Further studies will combine big data analytics with multivariate statistical analysis techniques by studying large health system performance data sets.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"40 ","pages":"Pages 100-107"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139088750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copyright/Subscription","authors":"","doi":"10.1016/S2212-1099(23)00136-X","DOIUrl":"https://doi.org/10.1016/S2212-1099(23)00136-X","url":null,"abstract":"","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"39 ","pages":"Page v"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221210992300136X/pdfft?md5=82f8ebfe0024661b03cdf56a00c0010c&pid=1-s2.0-S221210992300136X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139433367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric Properties of the Persian Dizziness Handicap Inventory – Screening Version","authors":"Sadegh Jafarzadeh PhD ,&nbsp;Jamshid Jamali PhD","doi":"10.1016/j.vhri.2023.10.011","DOIUrl":"10.1016/j.vhri.2023.10.011","url":null,"abstract":"<div><h3>Objectives</h3><p><span>The Dizziness Handicap Inventory (DHI) is the most popular and widely used questionnaire in evaluating patients with </span>vertigo<span>. This questionnaire has a screening version with a high correlation with DHI. This study aimed to assess the psychometric properties of the Persian DHI – Screening version (DHI-S).</span></p></div><div><h3>Methods</h3><p><span><span>This cross-sectional and methodological study was conducted on 300 patients at the central vestibular clinic in Mashhad, Iran, from 2020 to 2021. First, the DHI-S was translated into Persian using the backward-forward translation method. Subsequently, the following types of validity and reliability were examined: content validity based on content validity index and content validity ratio, face validity based on impact score, construct validity based on </span>confirmatory factor analysis, internal consistency based on Cronbach’s α and Ω, and test-retest stability based on intraclass </span>correlation coefficient and smallest detectable change.</p></div><div><h3>Results</h3><p>The DHI-S had high content and face validity. Score 8 was selected for the cutoff point between patients and the normal group with a sensitivity of 63.67% and specificity of 96.08%. The construct validity indicated that the questionnaire is one-dimensional. The Cronbach’s α and Ω for internal consistency were 0.855 and 0.851, respectively. The intraclass correlation coefficient was 0.981 and the smallest detectable change was 5.521.</p></div><div><h3>Conclusions</h3><p>The DHI-S in the Persian language has high and acceptable psychometric properties. This questionnaire can be used in research and clinical settings.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"41 ","pages":"Pages 1-6"},"PeriodicalIF":2.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating the Costs of End-of-Life Care in Patients With Advanced Cancer From the Perspective of an Insurance Organization: A Cross-Sectional Study in Iran","authors":"Ali Zafari MD ,&nbsp;Parisa Mehdizadeh PhD ,&nbsp;Mohammadkarim Bahadori PhD ,&nbsp;Nooredin Dopeykar MSc ,&nbsp;Ehsan Teymourzadeh PhD ,&nbsp;Ramin Ravangard PhD","doi":"10.1016/j.vhri.2023.11.006","DOIUrl":"10.1016/j.vhri.2023.11.006","url":null,"abstract":"<div><h3>Objectives</h3><p><span>Cancers are significant medical conditions that contribute to the rising costs of healthcare systems and chronic diseases. This study aimed to estimate the average costs of medical services provided to patients with advanced cancers at the </span>end of life (EOL).</p></div><div><h3>Methods</h3><p>We analyzed data from the Sata insurance claim database and the Health Information System of Baqiyatallah hospital in Iran. The study included all adult decedents who had advanced cancer without comorbidities, died between March 2020 and September 2020, and had a history of hospitalization in the hospital. We calculated the average total cost of healthcare services per patient during the EOL period, including both cancer-related and noncancer-related costs.</p></div><div><h3>Results</h3><p>A total of 220 patients met the inclusion criteria. The average duration of the EOL period for these patients was 178 days, with an average total cost of $8278 (SD $5698) for men and $9396 (SD $6593) for women. Cancer-related costs accounted for 64.42% of the total costs, including inpatient and outpatient services. Among these costs, hospitalization was the primary cost driver and had the greatest impact on EOL costs. This observation was supported by the multiple linear regression<span> model, which suggested that hospitalization in the final days of life could potentially drive costs in these patients. Notably, no specialized palliative care was provided to the patients included in this study.</span></p></div><div><h3>Conclusions</h3><p>The results demonstrate that there is a significant rise in costs of care in patients receiving routine cancer care rather than optimized EOL care.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"41 ","pages":"Pages 7-14"},"PeriodicalIF":2.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139058787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic Evaluation of Neoadjuvant Versus Adjuvant Chemotherapy in Cancer Treatment: A Systematic Review and Meta-Analysis","authors":"Dongdong Wu PhD ,&nbsp;Na Wang PhD ,&nbsp;Rufu Xu PhD ,&nbsp;Guoqiong Huang PhD ,&nbsp;Ying Li PhD ,&nbsp;Chunji Huang PhD","doi":"10.1016/j.vhri.2023.11.005","DOIUrl":"10.1016/j.vhri.2023.11.005","url":null,"abstract":"<div><h3>Objectives</h3><p><span><span>In the absence of evidence on whether neoadjuvant (NAC) or adjuvant chemotherapy (AC) is more beneficial for various </span>tumor treatments<span>, economic evaluation (EE) can assist medical decision making. There is limited evidence on their cost-effectiveness and their prospective evaluation is less likely in the future. Therefore, a </span></span>systematic review<span><span> and meta-analysis about EE for NAC versus AC in </span>solid tumor help compare these therapies from various perspectives.</span></p></div><div><h3>Methods</h3><p>Various databases were searched for studies published from inception to 2021. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines and economic-specific guidelines. The data were pooled using a random effects model when possible.</p></div><div><h3>Results</h3><p><span>The retrieval identified 15 EE studies of NAC versus AC in 8 types of cancer. NAC is the dominant strategy for pancreatic, head and neck, rectal, prostate cancers and </span>colorectal liver metastases. For ovarian cancer, NAC is cost-effective with a lower cost and higher or similar quality-adjusted life-year. There were no significant differences in cost and outcomes for lung cancer. For stage IV or high-risk patients with ovarian or prostate cancer, NAC was cost-effective but not for patients who were not high risk.</p></div><div><h3>Conclusions</h3><p>The EEs results for NAC versus AC were inconsistent because of their different model structures, assumptions, cost inclusions, and a shortage of studies. There are multiple sources of heterogeneity across EEs evidence synthesis. More high-quality EE studies on NAC versus AC in initial cancer treatment are necessary.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"41 ","pages":"Pages 15-24"},"PeriodicalIF":2.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139058734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Financial Toxicity Experiences of Patients With Cancer in Indonesia: An Interpretive Phenomenological Analysis","authors":"Stevanus Pangestu MBA ,&nbsp;Enggar Putri Harjanti MA ,&nbsp;Ika Hana Pertiwi MA ,&nbsp;Fanni Rencz MD, PhD ,&nbsp;F.A. Nurdiyanto MA","doi":"10.1016/j.vhri.2023.11.007","DOIUrl":"10.1016/j.vhri.2023.11.007","url":null,"abstract":"<div><h3>Objectives</h3><p>Financial toxicity (FT) is an important adverse effect of cancer. Recent systematic reviews have shown that FT may lead to treatment nonadherence and impaired health-related quality of life, both of which may adversely influence the survival rates of patients. However, less is known about how patients endure FT, particularly in low- and middle-income countries. The purpose of this study was to explore how patients with cancer experience and cope with FT in Indonesia.</p></div><div><h3>Methods</h3><p>Semistructured in-depth interviews were conducted to explore the experiences of Indonesian patients with cancer. Qualitative data were analyzed using interpretive phenomenological analysis approach. We purposefully recruited 8 patients undergoing active treatment (aged 27-69 years) who had been diagnosed of cancer over 5 years before and possessed health insurance at the time of diagnosis.</p></div><div><h3>Results</h3><p>We identified 2 main themes: (1) the experienced financial burden, with subthemes underinsurance, out-of-pocket nonhealthcare cancer-related costs, and negative income effect from employment disruption, and (2) the financial coping strategies, with subthemes reallocating household budget, seeking family support, rationalizing treatment decisions, and topping up insurance for family members.</p></div><div><h3>Conclusions</h3><p>This is the first interpretive phenomenological study on FT in the literature and the first qualitative FT study in Indonesia. Our findings provide insight into the occurrence of FT and coping strategies used by Indonesian patients with cancer. The subjective experiences of patients may be considered to further improve oncology care, support the need for measurement of FT, and provide mitigation programs for patients.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"41 ","pages":"Pages 25-31"},"PeriodicalIF":2.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212109923001310/pdfft?md5=1ebaa4776c46e4bad2aa3d4e3c1200a2&pid=1-s2.0-S2212109923001310-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139058788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}